

Resource Summary Report

Generated by [RRID](#) on Sep 6, 2026

Anti-N6-methyladenosine (m6A) antibody

RRID:AB_2753144

Type: Antibody

Proper Citation

Abcam Cat# ab151230, RRID:AB_2753144

Antibody Information

URL: http://antibodyregistry.org/AB_2753144

Proper Citation: Abcam Cat# ab151230, RRID:AB_2753144

Target Antigen: m6A

Host Organism: rabbit

Clonality: polyclonal

Comments: Applications: Nucleotide Array

Antibody Name: Anti-N6-methyladenosine (m6A) antibody

Description: This polyclonal targets m6A

Target Organism: dmelanogaster, mouse, human

Antibody ID: AB_2753144

Vendor: Abcam

Catalog Number: ab151230

Record Creation Time: 20231110T033339+0000

Record Last Update: 20260901T003151+0000

Ratings and Alerts

No rating or validation information has been found for Anti-N6-methyladenosine (m6A) antibody.

No alerts have been found for Anti-N6-methyladenosine (m6A) antibody.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 26 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Templeton CW, et al. (2026) N(6)-methyladenosine modification of RNA is regulated by senataxin and E6 to control HPV replication. *Cell reports*, 45(1), 116828.

Monteagudo-García Ó, et al. (2026) ZC3H13 Loss Drives Cancer Metastatic Progression by Disrupting m6A RNA Methylation. *Cancer research*, 86(3), 622.

Zhang Y, et al. (2026) FTO Regulates Autophagy and Energy Metabolism in Sepsis-Induced Cardiomyopathy: Insights From Integrated Transcriptome and Proteome Analysis. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology*, 40(11), e71985.

Cai F, et al. (2026) Loganin triggers ferroptosis in renal cell carcinoma by targeting the IGF2BP2/HMOX1 axis in an m6A-dependent manner. *Biochemical pharmacology*, 252, 118202.

Wang W, et al. (2025) Zbtb16 determines the fate plasticity of cardiovascular progenitors through IGF2BP3-mediated mRNA stabilization. *Cell reports*, 44(8), 116127.

Zhou Y, et al. (2025) Unlocking NAC's potential ATF4 and m6A dynamics in rescuing cognitive impairments in PTSD. *Metabolic brain disease*, 40(2), 129.

Hao JD, et al. (2024) DDX21 mediates co-transcriptional RNA m6A modification to promote transcription termination and genome stability. *Molecular cell*, 84(9), 1711.

Cheng Y, et al. (2023) Decoding m6A RNA methylome identifies PRMT6-regulated lipid transport promoting AML stem cell maintenance. *Cell stem cell*, 30(1), 69.

Loedige I, et al. (2023) mRNA stability and m6A are major determinants of subcellular mRNA localization in neurons. *Molecular cell*, 83(15), 2709.

Fang Q, et al. (2023) YTHDF1 phase separation triggers the fate transition of spermatogonial stem cells by activating the I β B-NF- κ B-CCND1 axis. *Cell reports*, 42(4), 112403.

Mukhopadhyay S, et al. (2023) eIF3d controls the persistent integrated stress response. *Molecular cell*, 83(18), 3303.

Debo BM, et al. (2023) Evaluation of N 6-methyldeoxyadenosine antibody-based genomic profiling in eukaryotes. *Genome research*, 33(3), 427.

Shen Q, et al. (2022) TFAP4 Activates IGF2BP1 and Promotes Progression of Non-Small Cell Lung Cancer by Stabilizing TK1 Expression through m6A Modification. *Molecular cancer research : MCR*, 20(12), 1763.

Li N, et al. (2022) Detection of N6-methyladenosine in SARS-CoV-2 RNA by methylated RNA immunoprecipitation sequencing. *STAR protocols*, 3(1), 101067.

Chen J, et al. (2022) TBK1-METTL3 axis facilitates antiviral immunity. *Cell reports*, 38(7), 110373.

Yin R, et al. (2022) Differential m6A RNA landscapes across hematopoiesis reveal a role for IGF2BP2 in preserving hematopoietic stem cell function. *Cell stem cell*, 29(1), 149.

Choi SH, et al. (2022) RBM45 is an m6A-binding protein that affects neuronal differentiation and the splicing of a subset of mRNAs. *Cell reports*, 40(9), 111293.

Liu Y, et al. (2021) Tumors exploit FTO-mediated regulation of glycolytic metabolism to evade immune surveillance. *Cell metabolism*, 33(6), 1221.

Cotter KA, et al. (2021) Mapping of m6A and Its Regulatory Targets in Prostate Cancer Reveals a METTL3-Low Induction of Therapy Resistance. *Molecular cancer research : MCR*, 19(8), 1398.

Wang X, et al. (2021) N6-methyladenosine modification of MALAT1 promotes metastasis via reshaping nuclear speckles. *Developmental cell*, 56(5), 702.